Between January, 1984, and December, 1990, a total of 85 patients have undergone stereotactic third ventriculostomy (TV) at the Mayo Clinic. Sixty-one patients (74%) presented with mass lesions in the region of the posterior third ventricle, aqueduct of Sylvius or fouth ventricle. Twenty-four patients (26%) presented with non-tumoral, adult/adolescent-onset aqueductal stenosis. Follow-up was available for all 85 patients and ranged from 1 to 66 months (mean 25 months). Follow-up revealed initial patency in 84 patients. Eleven patients (13%) ultimately required extracranial shunting for persistent symptomatic hydrocephalus. Two patients underwent revision of their TV. Twenty-seven patients had been previously shunted. Of these, 23 (85%) have remained asymptomatic after TV without the need for further shunting. Stereotactic TV is a safe and effective way of re-establishing normal cerebrospinal fluid flow dynamics in selected cases of obstructive hydrocephalus.

Keywords:
Hydrocephalus, Third ventriculostomy, Aqueductal Stenosis, CNS neoplasm, Shunts
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.